Zomedica (NYSEAMERICAN:ZOM) Issues Quarterly Earnings Results

Zomedica (NYSEAMERICAN:ZOM – Get Rating) posted its quarterly earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, Yahoo Finance reports. The company had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.20 million. Zomedica had a negative return on equity of 6.51% and a negative net margin of 104.92%.

Zomedica Trading Down 2.6 %

ZOM stock traded down $0.01 during trading on Friday, reaching $0.23. The company had a trading volume of 945,000 shares, compared to its average volume of 10,059,181. Zomedica has a twelve month low of $0.15 and a twelve month high of $0.41.

Analyst Ratings Changes

Separately, Dawson James began coverage on shares of Zomedica in a research report on Friday, January 6th. They set a “buy” rating and a $6.00 target price on the stock.

Institutional Trading of Zomedica

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC purchased a new position in Zomedica during the 2nd quarter worth approximately $552,000. Vanguard Group Inc. raised its position in Zomedica by 5.1% during the 3rd quarter. Vanguard Group Inc. now owns 46,329,005 shares of the company’s stock worth $9,775,000 after buying an additional 2,252,651 shares during the last quarter. Jane Street Group LLC raised its position in Zomedica by 413.9% during the 2nd quarter. Jane Street Group LLC now owns 1,082,261 shares of the company’s stock worth $238,000 after buying an additional 871,646 shares during the last quarter. BlackRock Inc. raised its position in Zomedica by 5.6% during the 1st quarter. BlackRock Inc. now owns 13,418,299 shares of the company’s stock worth $4,523,000 after buying an additional 707,993 shares during the last quarter. Finally, Millennium Management LLC raised its position in Zomedica by 240.8% during the 2nd quarter. Millennium Management LLC now owns 557,672 shares of the company’s stock worth $123,000 after buying an additional 394,058 shares during the last quarter. 9.42% of the stock is currently owned by institutional investors and hedge funds.

Zomedica Company Profile

(Get Rating)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.